 Rich Picks Daily is an online community for traders to exchange smart, straightforward, and profitable investment ideas. Join us today at richpicksdaily.com, subscribe to us on YouTube to learn useful stock trading secrets and discover the next ten-banker. Hey, how you doing? This is Rich from Rich TV Live, and I wanted to talk to you about some big news that came out from Valeo Pharma. You can see the symbol in America, V-P-H-I-F, and in Canada, V-P-H, Valeo Pharma, you can see currently at $1.14. And they had some big news, we're going to go over it. These are all the different pieces of news that came out, but this is the big news for Valeo Pharma. You can see right here the market cap, only a 74 million market cap, only 65 million shares issued an outstanding very, very, very tight flow. Love that. And this is the big news. Valeo Pharma Inc. enters into an agreement for N-A-Zare, Breathalyre, and Atakura, breathalyre in Canada. Valeo to commercialize N-A-Zare, Breathalyre, and Atakura, Breathalyre, two innovative asthma therapies approved by Health Canada. Positions Valeo as one of the leading Canadian respiratory companies, almost four million Canadians affected with asthma, afflicted with asthma. Canadian market for asthma medication exceeds 700 million annually. This was on March 29, 2021. Valeo Pharma, as you can see, VPH in Canada, VPH IF in America, and VP2 in Frankfurt, Germany. Pharmaceutical company announced today it has entered into a commercialization and supply agreement with Novartis Pharmaceuticals Inc. for the Canadian commercialization by Valeo of two asthma therapies, N-A-Zare and Breathalyre. Under the agreement, Valeo will be responsible for medical and commercial activities for N-A-Zare, Breathalyre, and Atakura, breathalyre for an initial eight-year period. At present, almost four million Canadians are living with asthma, a serious health issue affecting all age groups, patients with severe asthma live in fear of potentially exacerbations, which remain highly prevalent even with today's most advanced therapies. Asthma-related exacerbations are concerning because of their association and associated to mortality, burden, and also because of the increased risk of side effects from the use of systematic systemic cortisosteroids. Furthermore, there is growing evidence highlighting the lack of system control currently achieved in asthma. 39% of patients remain uncontrolled despite available dual laba slash ICS medications primarily due to low adherence, treatment, misuse, and poor inhaler technique. There is an urgent need to add effective maintenance treatment options to more efficiently address symptoms as well as asthma-related long-term complications and mortality. We are extremely pleased to be partnering with Novartis to launch these two asthma drugs in the coming weeks. This is huge, huge news for VALUFARMA, commercializing ennezer and breathalyre, and at Tectura, breathalyre will immediately position VALUFARMA as one of the leading Canadian respiratory companies providing first-in-class and best-in-class asthma therapies. The Canadian asthma maintenance market exceeds 700 million annually, said Steve Saviex, CEO of VALUFARMA. His partnership is perfectly aligned with VALUFARMA's vision and mission of building a Canadian anchor pharmaceutical company by driving therapeutic innovation to patients in need. We look forward to building a long and mutually beneficial relationship with Novartis that will help old companies fulfill their respective missions. This agreement with VALUFARMA fits with our overall strategy to provide innovative medicines that have the potential to improve health outcomes, said Andrea Marazzi and head country pharma organization Novartis Pharmaceuticals Canna Inc. VALUFARMA's commitment and focus to bring ennezer and breathalyre and at Tectura, breathalyre to Canadians, combined with our strong respiratory experience, brings a solution that will help make asthma control a more attainable goal for some Canadians. Commenting on this commercial agreement with Novartis, Frederick Fasano, VALUFARMA recently appointed president and CEO said, ennezer, breathalyre and at Tectura, breathalyre are both benefiting from an extensive phase three clinical trial program, including more than 7,500 asthma patients. The efficacy of both treatments on symptoms, lung function and rate of exasperations has been demonstrated and this will provide Canadian patients with a significant improvement over current standards of care. He added this significant addition to our expanding product portfolio is key to achieving our growth objectives. It will provide the basis for the upskilling of our organization to set the stage for future international expansion. The ennezer, breathalyre and at Tectura, breathalyre will both be available in the HFA slash CFC free breathalyre device. So this is the big news. Huge news for VALUFARMA and this is the news that broke last week. And you can see leading companies potentially unlock more advanced care therapy titles. And you can see here, they are noted here, VALUFARMA. They're noted with Pfizer, laboratories, ABVI and Gilead Sciences. Huge names. Have taken note of the challenges of managing these conditions and the potential of exasperations and worse outcomes for people with poorly managed conditions. They have developed drugs and advanced care therapies that improve the management of these conditions. These developments in the pharmaceutical industry open up a potential market opportunity for companies that are positioned to provide improved healthcare solutions, which include VALUFARMA to commercialize advanced asthma maintenance therapies in Canada. VALUFARMA is a Canadian pharmaceutical company committed to the commercialization of innovative prescription products in Canada with a focus on respiratory neurology, neurodegenerative diseases, oncology and specialty products. Company just recently announced a commercialization and supply agreement with Novartis, which I just spoke on, Pharmaceuticals Canada Inc, a company responsible for the development of two asthma therapies, N-Azare, Brasilaire and Actectura Brasilaire. The agreement gives VALUFARMA the responsibility of overseeing the medical and commercialization activities for the therapies for initial eight-year period. Pretty huge news, as you can see, and it is getting around. There are two, and here it is as well, VALUFARMA supplying Canadian market with effective asthma maintenance drugs. Did you know that over 25 million Americans have asthma worldwide? That number balloons to more than 339 million. If you yourself don't have it, then you probably know someone who does. So what's being done to help the situation? While there isn't a cure for asthma, there has been remarkable progress made in asthma treatments, and we've got just our hands on the pot of gold at the end of the asthmatic rainbow, or rather, VALUFARMA has VALUFARMA is a pharmaceutical company that dedicates itself to commercialization of innovative prescription products, and it just added two substantial asthma drugs to its diverse roster. Here's five reasons why VALUFARMA is unlike any other pharma stock and has a chance to explode. I told you guys that is a tight float, and now it's partnering with a giant growing product portfolio of unique and game-changing medications and therapies, including the latest editions of two asthma drugs focused on therapeutic markets with limited competition on oncology, hospital neurodegenerative disease treatment markets, strong revenue growth going forward, turning EBITDA positive, huge, turning EBITDA positive doesn't get better than that. All products are market ready, no cost, R&D or risk associated with lengthy trial periods, strong management, investor alignment with high level of insider ownership, 65% insider owned. So, lots of reasons why you would need to put VALUFARMA on your watch list, put it on your radar, price is right, tight float, and really, really big news with a giant Novartis. What do you guys think of this news? Remember, RISTV Live is strictly for education and entertainment purposes. Always do your due diligence, always do your research before you invest anything that we talk about here in RISTV Live, always invest in the best, the best is blessed, and you deserve the best. I think that these guys have a chance to be absolutely one of the best. What do you guys think? Be like the video, smash the like button, comment down below, share the video everywhere and subscribe. I think the price is still right, you know, at $1.14 and the potential to be a pharmaceutical giant, I think it's, I think it's great. What do you guys think? It's your boy, Rich from RISTV Live, if you're not winning, you're not watching. We bring in the winners and we bring them to you first. What do you think of VALUFARMA, $1.14 in Canada, V-P-H-I-F in America? Only 90 cents. What do you guys think? This is Rich from RISTV Live bringing you VALUFARMA, the big news right here, VALUFARMA Inc. Agreement for Enterzair, Breezellair and Actectura Breezellair in Canada. Comment down below. Let me know what you think. Subscribe if you're alive. This is your boy, Rich from RISTV Live and I'm out.